PT - JOURNAL ARTICLE AU - Aatresh, Aishani V. AU - Lipsitch, Marc TI - What is the relationship between viral prospecting in animals and medical countermeasure development? AID - 10.1101/2024.08.09.24311747 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.09.24311747 4099 - http://medrxiv.org/content/early/2024/08/10/2024.08.09.24311747.short 4100 - http://medrxiv.org/content/early/2024/08/10/2024.08.09.24311747.full AB - In recent decades, surveillance in nonhuman animals has aimed to detect novel viruses before they “spill over” to humans. However, the extent to which these viral prospecting efforts have enhanced preparedness for disease outbreaks remains poorly characterized, especially in terms of whether they are necessary, sufficient, or feasible ways to spur medical countermeasure development. We find that several viruses which pose known threats to human health lack approved vaccines and that known viruses discovered in human patients prior to 2000 have caused most major 21st-century outbreaks. With Filoviridae as a case study, we show there is little evidence to suggest that viral prospecting has accelerated countermeasure development or that systematically discovering novel zoonotic viruses in animal hosts before they cause human outbreaks has been feasible. These results suggest that prospecting for novel viral targets does not accelerate a rate-limiting step in countermeasure development and underscore questions about the importance of zoonotic viral discovery for outbreak preparedness. We consider limitations to these conclusions and alternative but related approaches to preparedness and response.Competing Interest StatementA.V.A. was an intern for CEPI in 2023 and is a consultant for Centivax, Inc. M.L. is on the Scientific Advisory Board for CEPI.Funding StatementM.L. thanks the VK fund for CCDD, Open Philanthropy, and the DALHAP fund for supporting this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used for this analysis are available in Supplementary Information.CEPICoalition for Epidemic Preparedness InnovationsDONDisease Outbreak NewsEVDEbola virus diseaseMCMmedical countermeasureMVDMarburg virus diseaseNIAIDNational Institute of Allergy and Infectious DiseasesPHEICPublic Health Emergency of International ConcernUKVNUK Vaccines Research and Development NetworkUSAIDUnited States Agency for International DevelopmentWHOWorld Health Organization